XPhyto Pursues Potential Application of its Oral Dissolvable Biosensor Inflammation Test for Buprenorphine-related Dental Disease - Seite 2

 

The Company is currently investigating the potential application of one or more of its oral health biosensor screening tests for the detection of buprenorphine-related dental problems. Requirements for clinical evaluation for the purpose of commercial registration and/or approval will be released once established. The company expects to provide further updates on its oral health and infectious disease screening test programs in the coming weeks.

 

XPhyto's pipeline of biosensor screening products for inflammatory, bacterial and viral infectious diseases includes stomatitis, periimplantitis, periodontitis, group A strep, influenza A, and covid-19. This suite of biosensor products positions the Company within the global biosensor and oral health markets which are expected to reach US$42 billion by 2027 according to Global Market Insights and MedicalExpo e-magazine and projected to reach US$698.8 billion by 2030.

 

About XPhyto Therapeutics Corp.

 

XPhyto Therapeutics Corp. is a diversified bioscience accelerator focused on next-generation drug formulation, diagnostic, and new active pharmaceutical ingredient investment opportunities, including: precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and manufacture, standardization, and evaluation of psychedelic compounds for the treatment of neurological conditions. The Company has research and development operations in North America and Europe, with an operational focus in Germany, and is currently focused on regulatory approval and commercialization of medical products for European markets.

 

XPhyto Therapeutics Corp.

Hugh Rogers, CEO and Director

Email: [e-mail]

Phone: [phone]

 

Raimar Löbenberg, PhD

Director, Drug Development and Innovation Centre

https://www.ualberta.ca/pharmacy/research/drug-development-and-innovat ...

Professor

Faculty of Pharmacy and Pharmaceutical Sciences

Katz Group-Rexall Centre for Pharmacy & Health Research

University of Alberta

11315 - 87 Avenue, Room 3-142-K

Edmonton, AB T6G 2T9

Phone: [phone]

Fax: [phone]

Skype: raimarloebenberg

 

Forward-Looking Statements